Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420852 | 1.00 | CYP3A4 (0.39) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL420861 | 1.00 | CYP3A4 (0.39) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL421045 | 1.00 | CYP3A4 (0.39) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL14944945 | 0.83 | CYP3A4 (0.34) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL14944938 | 0.83 | CYP3A4 (0.34) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL12905141 | 0.78 | GAA (0.42) | MEN1KMT2A | |
| SCHEMBL12952536 | 0.77 | CYP3A4 (0.31) | CYP3A4MAPK1 | |
| SCHEMBL12455836 | 0.75 | CYP3A4 (0.46) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL18476416 | 0.71 | — | — | |
| SCHEMBL12389690 | 0.69 | PABPC1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150141638-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140288024-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140072633-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20100285144-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288024-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | CYP3A4 3070/4885MAPK1 4700/4885MEN1 4477/4885 |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | CYP3A4 3070/4885MAPK1 4700/4885MEN1 4477/4885 |
| US-20140072633-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS OF USE | EPOR, TTPA, PSAP | CYP3A4 3727/4885MAPK1 4741/4885MEN1 1363/4885 |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CYP3A4 3210/4885MAPK1 4131/4885MEN1 2879/4885 |
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | DDOST, SDCBP, STT3B | CYP3A4 2989/4885MAPK1 4729/4885MEN1 4554/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | CYP3A4 4765/4885MAPK1 4572/4885MEN1 1397/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | CYP3A4 4765/4885MAPK1 4572/4885MEN1 1397/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | CYP3A4 3047/4885MAPK1 4795/4885MEN1 817/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | CYP3A4 4765/4885MAPK1 4572/4885MEN1 1397/4885 |
| US-20150141638-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | CYP3A4 3070/4885MAPK1 4700/4885MEN1 4477/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | CYP3A4 3047/4885MAPK1 4795/4885MEN1 817/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CYP3A4 3210/4885MAPK1 4131/4885MEN1 2879/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CYP3A4 3210/4885MAPK1 4131/4885MEN1 2879/4885 |
| US-20100285144-A1 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | EPOR, TTPA, PDS5A | CYP3A4 3769/4885MAPK1 4756/4885MEN1 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.